Penn Medicine Unveils the Pioneering King Center for Lynch Syndrome, Backed by a Landmark $10 Million Donation
In a groundbreaking advancement for hereditary cancer research and care, Penn Medicine has inaugurated the King Center for Lynch Syndrome, fortified by a transformative $10 million contribution from Cynthia King, the late Jeffery King, and Jason and Julie Borrelli. This initiative, established at the Abramson Cancer Center of the University of Pennsylvania, marks the world’s first named center exclusively dedicated to Lynch syndrome. This hereditary condition affects roughly 1 in 279 individuals in the United States, equating to an estimated 1.2 million people, and is known for significantly elevating the risk of colorectal and endometrial cancers, among others.
Lynch syndrome represents one of the most prevalent hereditary cancer syndromes identified to date, yet awareness remains alarmingly sparse. Dr. Bryson Katona, MD, PhD, co-founder and inaugural executive director of the King Center, emphasizes this gap in public consciousness: “Despite Lynch syndrome’s high incidence as a genetic cause of cancer, many affected individuals and healthcare providers remain unaware of its existence or implications.” The substantial donation from the King and Borrelli families aims to transform this landscape by expanding cutting-edge research endeavors, lifetime patient care strategies, and public education.
The genesis of this generous philanthropy is deeply personal. The King and Borrelli families have been long-standing proponents of Lynch syndrome research, motivated by intimate battles with the condition. The late Jeffery King’s diagnosis in his late sixties, following a second Lynch-related cancer, underscores the critical need for early detection and awareness. His daughter, Julie Borrelli, contrasts her experience, having accessed genetic testing and personalized cancer risk management at a much earlier age, demonstrating the tangible benefits of proactive intervention.
At a molecular level, Lynch syndrome arises from germline mutations in critical DNA mismatch repair (MMR) genes—MLH1, MSH2, MSH6, PMS2, and EPCAM. These genes function as guardians of genomic integrity by correcting replication errors that, if unchecked, predispose cells to malignant transformation. Dysfunctional MMR due to hereditary mutations compromises this surveillance system, precipitating microsatellite instability and an increased mutational burden that propels oncogenesis across various tissues.
The clinical consequences of Lynch syndrome are profound. While the general population faces about a 4% lifetime risk of colorectal cancer and approximately 3% for uterine cancer, individuals with Lynch syndrome can see these risks soar dramatically—ranging from 9% to 60% for colorectal cancer, and between 13% to nearly 60% for endometrial cancer, depending on their specific mutational profile. Additional malignancies such as gastric, urinary tract, pancreatic, ovarian, and certain skin cancers also occur with elevated likelihood, though to a lesser degree.
Managing this heightened risk requires a comprehensive, personalized paradigm. Lynch syndrome carriers necessitate intensified surveillance regimens that commence earlier and occur more frequently than standard population guidelines. The multifaceted nature of associated cancer risks demands an expert coordinator—typically a Lynch syndrome specialist—to orchestrate and tailor screenings across organ systems. This ensures no aspect of the hereditary risk spectrum is overlooked, fostering timely detection and prevention.
However, clinical management challenges persist. According to Jessica Long, MS, CGC, director of education and outreach for the King Center, many patients undergo colonoscopies without comprehensive counseling on their uterine cancer risk or proactive familial risk assessment. This fragmented care underscores the importance of centralized expertise capable of delivering holistic, evidence-based surveillance and facilitating genetic counseling for affected families.
Beyond clinical care, Lynch syndrome research is rapidly evolving. The King Center supports a robust research portfolio spanning basic science, translational studies, and clinical trials, empowered by philanthropic funding. Remarkably, over 1,200 blood samples and extensive biopsy and stool collection cohorts enrich the Lynch Syndrome Immune Profiling Project at Penn, enabling scientists to interrogate immune mechanisms that modulate individual cancer risk variability.
Dr. E. John Wherry, PhD, co-founder of the King Center and chair of the Department of Systems Pharmacology and Translational Therapeutics, highlights the intriguing heterogeneity in cancer risk manifestation among Lynch syndrome carriers. His research explores the interplay between tumor immunology and genetic susceptibility, aspiring to refine personalized risk predictions and devise tailored immunotherapeutic strategies that preempt cancer development in these high-risk populations.
Currently, close to 1,000 patients receiving care at Penn Medicine for Lynch syndrome—many of whom traverse significant distances within the Northeast to access expert services—benefit from multidisciplinary approaches that integrate leading-edge genomics, immunology, and oncology. The King Center will amplify these efforts by expanding education initiatives for patients, families, and healthcare professionals, and by accelerating clinical trial enrollment targeting novel therapies and early detection methodologies.
In addition to patient-centered advancements, the King Center endeavors to fortify public health outreach by raising Lynch syndrome awareness, thereby bridging the knowledge deficit that impedes widespread genetic testing and surveillance adoption. Events such as the upcoming 5th Annual Lynch Syndrome Symposium serve as vital platforms for disseminating the latest research findings, clinical guidelines, and innovations in risk management.
The establishment of the King Center for Lynch Syndrome represents a transformative milestone, poised to catalyze significant progress in understanding and combating hereditary cancer risk. By marrying philanthropic vision with scientific rigor and compassionate care, Penn Medicine reaffirms its commitment to revolutionizing oncology and empowering individuals with Lynch syndrome to live longer, healthier lives.
Subject of Research: Lynch syndrome hereditary cancer research and patient care innovation
Article Title: Penn Medicine Launches World’s First Named Center for Lynch Syndrome with $10 Million Philanthropic Gift
News Publication Date: March 2026
Web References:
– King Center for Lynch Syndrome: https://www.med.upenn.edu/kingcenter/
– Lynch Syndrome Information: https://www.pennmedicine.org/conditions/lynch-syndrome
– Abramson Cancer Center: https://www.pennmedicine.org/specialties/cancer/about-abramson-cancer-center
Keywords: Lynch syndrome, hereditary cancer, DNA mismatch repair, colorectal cancer, endometrial cancer, cancer genetics, personalized cancer risk management, genetic counseling, cancer screening, immunology, translational research, Penn Medicine, Abramson Cancer Center
Tags: $10 million medical donationAbramson Cancer Center initiativesDr. Bryson Katona Lynch syndromeendometrial cancer genetic riskgenetic cancer syndromes awarenesshereditary cancer research fundinghereditary cancer syndrome statisticshereditary colorectal cancer riskKing Center for Lynch SyndromeLynch syndrome hereditary cancer researchLynch syndrome patient care advancementsPenn Medicine cancer research
